FDA Approves Pizensy (lactitol) for the Treatment of Chronic Idiopathic Constipation in Adults
Braintree, Mass. March 02, 2020 -- Sebela Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Pizensy (lactitol) for oral solution for the once-daily treatment of chronic idiopathic constipation (CIC)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 2, 2020 Category: Drugs & Pharmacology Source Type: news
AstraZeneca divests global rights to Movantik
AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). (Source: World Pharma News)
Source: World Pharma News - February 25, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
FDA OKs New Drug for Chronic Idiopathic Constipation FDA OKs New Drug for Chronic Idiopathic Constipation
Lactitol (Pizensy) is an osmotic laxative taken once daily for treatment in adults with chronic idiopathic constipation.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 13, 2020 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news
Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “While we contin...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
